Physiologically Based Pharmacokinetic Modeling and Simulations in Lieu of Clinical Pharmacology Studies to Support the New Drug Application of Asciminib

<b>Background</b>: Asciminib (Scemblix^®) is approved for the first-line treatment of adult patients with chronic myeloid leukemia in the chronic phase at 40 mg twice daily (BID) and 80 mg once daily (QD) or 200 mg BID for patients harboring the T315I mutation. <...

詳細記述

書誌詳細

出版年:	Pharmaceutics
主要な著者:	Ioannis Loisios-Konstantinidis, Felix Huth, Matthias Hoch, Heidi J. Einolf
フォーマット:	論文
言語:	英語
出版事項:	MDPI AG 2025-09-01
主題:	asciminib PBPK modeling and simulation drug–drug interactions clinical pharmacology chronic myeloid leukemia
オンライン･アクセス:	https://www.mdpi.com/1999-4923/17/10/1266